The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for…

Attempts to restrict pharmaceutical advertisements have failed many times over the years, often on First Amendment grounds.

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

Donald Trump sued the Pulitzer Prize Board over its 2022 statement reaffirming its decision to award a prize for coverage of the 2016 Trump campaign’s…

The shot is no longer being manufactured or supplied, and it is no longer authorized for use in Europe.

Kevin Plank, the sports apparel company’s controlling shareholder, will seek to reinvigorate the struggling brand.

The pharmaceutical company will give up its ownership rights to the drug and stop a clinical trial that had been aimed at confirming whether it…

Starting April 1, state employees in North Carolina will no longer have insurance coverage for costly weight-loss medications like Wegovy and Zepbound.

Many employers and government programs won’t cover costly obesity medications. A lawsuit is challenging one such policy.

Experts say the exploitation of a loophole in the patent system has contributed to high prices for inhalers.